Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SH) Latest Company News

Oct 26, 2026, 09:07 UTC
Wantai BioPharm reported revenue of 1.623 billion yuan and a net loss attributable to shareholders of 231 million yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 26, 2026, 09:07 UTC
Wantai BioPharm reported third-quarter 2026 revenue of 574 million yuan, down 12.33% year over year, and a net loss attributable to shareholders of 102 million yuan.
Source:
- finance.sina.cn
Oct 12, 2026, 07:59 UTC
China’s National Medical Products Administration approved clinical trials of Wantai Canghai’s RSV vaccine for preventing RSV-related lower respiratory tract disease in people aged 60 and older.
Source:
- finance.sina.cn
Oct 9, 2026, 09:48 UTC
Turkey’s Medicines and Medical Devices Agency issued a GMP certificate after WanTai Bio-Pharm’s wholly owned subsidiary Xiamen Innovax Biotech’s nine-valent HPV vaccine production line passed a GMP compliance inspection.
Source:
- finance.sina.cn
Sep 7, 2026, 10:40 UTC
Wantai Biological announced plans to terminate its 2021 private placement project for a 20-valent pneumococcal polysaccharide conjugate vaccine and redirect the remaining raised funds of 455 million yuan to a new high-valent pneumococcal polysaccharide conjugate vaccine project with a total investment of 2.437 billion yuan.
Source:
- finance.sina.cn
Aug 19, 2026, 08:28 UTC
Wantai Biological announced its first-half 2026 results: revenue of 1.048 billion yuan, up 24.29% year-on-year, and a net loss attributable to shareholders of 128 million yuan, compared with a loss of 144 million yuan in the same period last year.
Source:
- finance.sina.cn
- wap.eastmoney.com
Jul 3, 2026, 07:37 UTC
Wantai Biological's director and general manager JIANG ZHIMING resigned on July 2, 2026, and chairman Qiu Zixin will temporarily assume the general manager duties.
Source:
- finance.sina.cn
- nbd.com.cn

603392.SH

Wantai BioPharm reported revenue of 1.623 billion yuan and a net loss attributable to shareholders of 231 million yuan for the first three quarters of 2026.

Wantai BioPharm reported third-quarter 2026 revenue of 574 million yuan, down 12.33% year over year, and a net loss attributable to shareholders of 102 million yuan.

China’s National Medical Products Administration approved clinical trials of Wantai Canghai’s RSV vaccine for preventing RSV-related lower respiratory tract disease in people aged 60 and older.

Turkey’s Medicines and Medical Devices Agency issued a GMP certificate after WanTai Bio-Pharm’s wholly owned subsidiary Xiamen Innovax Biotech’s nine-valent HPV vaccine production line passed a GMP compliance inspection.

Wantai Biological announced its first-half 2026 results: revenue of 1.048 billion yuan, up 24.29% year-on-year, and a net loss attributable to shareholders of 128 million yuan, compared with a loss of 144 million yuan in the same period last year.

Wantai Biological's director and general manager JIANG ZHIMING resigned on July 2, 2026, and chairman Qiu Zixin will temporarily assume the general manager duties.